The Institute for Clinical and Economic Review, commonly referred to as ICER, has long been viewed as the “nerds” of the drug industry. They are typically seen as bespectacled killjoys who emerge from their seclusion only a few times a year to criticize pharmaceutical companies for overpricing their latest cancer or MS treatments.
However, last year, ICER shocked many with its decision that a new treatment was worth up to $3.9 million – more than any other medicine in history and equivalent to a 45-year supply of Humira, a commonly used autoimmune drug. This decision demonstrated the extraordinary potential of a new class of gene therapies to provide genuine cures, something that the pharmaceutical industry rarely accomplishes.
The treatment, now approved as Lenmeldy, offers hope to babies born with metachromatic leukodystrophy (MLD), an ultra-rare neurodegenerative disease. Lenmeldy may enable these infants to grow up and lead essentially normal lives, representing a significant breakthrough in medical science.
Clayton Nylund, a science teacher at Blake High School in Hillsborough County, has been named…
Ubisoft, a leading producer of open-world games, has announced its plans to regain its position…
I am excited to announce the release of my new book in June. The inspiration…
In an effort to expand its reach and create job opportunities in local communities, Health…
After 27 years of operation, the Siegen Marketplace location of Chili's in Baton Rouge has…
During a visit to Kyiv, Secretary of State Antony Blinken reaffirmed the United States' commitment…